ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...

A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

QUEENSBURY, N.Y., December 31, 2025--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and ...

These subgroup analyses add to the existing evidence of bempedoic acid as an effective treatment for the reduction of cardiovascular risk. MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe GmbH ...

Claims of differential treatment effects were largely rated as “low credibility” or “very low credibility.” Subgroup analyses in cancer trials may not be credible, and their results should be ...

Median progression-free survival (PFS) in pancreatic neuroendocrine tumor (P-NET) patients was 24.5 months on 177 Lu-edotreotide arm vs. 14.7 months on everolimus arm Objective response rate (ORR) was ...

Myosteatosis on computed tomography as a predictor of therapeutic response to CDK4/6 inhibitors plus aromatase inhibitors in patients with advanced breast cancer. Subgroup OS HR (95% CI) OS p-value ...

This article was adapted from STAT’s latest report, “Subgroup analysis: how to evaluate post hoc tests for significance in failed clinical trials.” Clinical trials of newly developed drugs often don’t ...

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma A total of 221 publications reporting data on ...

Median progression-free survival (PFS) in pancreatic neuroendocrine tumor (P-NET) patients was 24.5 months on ...